ARK Genomic Revolution ETF

$28.36

+0.51 (+1.83%)

Fund Overview by ARK Invest

Actively managed fund focused on the genomic revolution: gene editing (CRISPR), molecular diagnostics, targeted therapeutics, stem cells, and agricultural biology. High-conviction positions in companies reshaping medicine.

AUM$1.8B

Expense Ratio0.75%

Holdings35

Dividend Yield0.0%

DistributionAnnually

BenchmarkNone (Active)

InceptionOct 2014

ExchangeNYSEARCA

Price Data

Open$28.22

Prev Close$27.85

Day Range$28.08 — $29.15

Genomics ETF Comparison

ETF	Price	Change	Expense	AUM	Holdings	Yield
ARKG ARK Genomic Revolution ETF	$28.36	+1.83%	0.75%	$1.8B	35	0.0%
IBB iShares Biotechnology ETF	$175.03	+0.15%	0.44%	$7.8B	224	0.2%
XBI SPDR S&P Biotech ETF	$126.74	+0.91%	0.35%	$6.5B	145	0.1%

Top Genomics Stocks View all →

Stock	Price	Change	Market Cap
ABBV Abbvie Inc	$228.72	-1.78%	397.77B
AMGN Amgen Inc	$375.50	-1.11%	203.62B
GILD Gilead Sciences Inc	$151.12	-1.06%	187.49B
VRTX Vertex Pharmaceuticals Inc	$469.27	-0.22%	124.10B
REGN Regeneron Pharmaceuticals	$782.38	-1.23%	82.83B
ALNY Alnylam Pharmaceuticals Inc	$340.11	+0.22%	43.84B
INSM Insmed Inc	$149.86	-0.77%	33.81B
NTRA Natera Inc	$216.71	+0.16%	29.93B
BIIB Biogen Inc	$201.18	+8.53%	28.17B
UTHR United Therapeutics Corp	$475.11	-1.13%	20.54B

ARKG FAQ

What is ARKG?

ARKG is the ARK Genomic Revolution ETF, an exchange-traded fund managed by ARK Invest. It tracks the None (Active) and holds 35 Genomics securities with an expense ratio of 0.75%.

What is the expense ratio of ARKG?

ARKG charges an annual expense ratio of 0.75%, which means you pay $75.00 per year for every $10,000 invested. This fee is deducted automatically from the fund's returns.

What are the alternatives to ARKG?

Other genomics ETFs include IBB, XBI. Each offers different expense ratios, weighting methodologies, and number of holdings. Compare them in the ETF comparison table above to find the best fit for your portfolio.

Explore Genomics Stocks

View our full list of individual genomics stocks with prices, fundamentals, and analyst ratings.

View List →

Last updated: Feb 15, 2026 at 12:57 AM ET